MSMariana Mendonça Soares

Mariana Mendonça Soares

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mariana Mendonça Soares has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardiotonic Steroids as a Potential Novel Approach for Immunomodulation in Inflammatory Bowel Disease

    by Luiz Henrique Agra Cavalcante-Silva, José Marreiro de Sales-Neto, Mariana Mendonça Soares, Davi Azevedo Ferreira, Anna Beatriz Araujo Medeiros, Sandra Rodrigues-Mascarenhas

    Inflammatory bowel disease (IBD) is a chronic condition that significantly impairs the quality of life of millions of individuals. The pathogenesis of IBD is closely linked to dysbiosis of microbiota and the activation of various inflammatory pathways, which are characterized by elevated levels of activated immune cells, such as neutrophils and lymphocytes. While several therapeutic options, including corticosteroids and biologic agents, are available for the treatment of IBD, their efficacy remains limited. Consequently, the development of novel therapies is essential. In this context, cardiotonic steroids, a class of drugs traditionally known for their effects on the cardiovascular system, have gained attention due to their potential immunomodulatory properties. Thus, this review aims to explore the emerging therapeutic potential of cardiotonic steroids in the treatment of IBD.

  • Open Access

    Evaluation of Anti-Inflammatory Activity of the New Cardiotonic Steroid γ-Benzylidene Digoxin 8 (BD-8) in Mice

    by Davi Azevedo Ferreira, Anna Beatriz Araujo Medeiros, Mariana Mendonça Soares, Éssia de Almeida Lima, Gabriela Carolina Santos Lima de Oliveira, Mateus Bernardo da Silva Leite, Matheus Vieira Machado, José Augusto Ferreira Perez Villar, Leandro Augusto Barbosa, Cristoforo Scavone, et al.

    Cardiotonic steroids are known to bind to Na+/K+-ATPase and regulate several biological processes, including the immune response. The synthetic cardiotonic steroid γ-Benzylidene Digoxin 8 (BD-8) is emerging as a promising immunomodulatory molecule, although it has remained largely unexplored. Therefore, we tested the immunomodulatory potential of BD-8 both in vitro and in vivo. Hence, primary mouse macrophages were incubated with combinations of BD-8 and the pro-inflammatory fungal protein zymosan (ZYM). Nitric oxide (NO) production was determined by Griess reagent and cytokines production was assessed by enzyme-linked immunosorbent assay. Inducible nitric oxide synthase (iNOS), reactive oxygen species (ROS), p-nuclear factor kappa B p65 (NF-κB p65), p-extracellular signal-regulated kinase (p-ERK), and p-p38 were evaluated by flow cytometry. Macrophages exposed to BD-8 displayed reduced phagocytic activity, NO levels, and production of the proinflammatory cytokine IL-1β induced by ZYM. Furthermore, BD-8 diminished the expression of iNOS and phosphorylation of NF-κB p65, ERK, and p38. Additionally, BD-8 exhibited anti-inflammatory capacity in vivo in a carrageenan-induced mouse paw edema model. Taken together, these findings demonstrate the anti-inflammatory activity of BD-8 and further reinforce the potential of cardiotonic steroids and their derivatives as immunomodulatory molecules.